PT-141

PT-141 is the only peptide on this site approved by the FDA specifically for sexual function, and the approval chronology is unusual: the original development program targeted male erectile dysfunction by an intranasal route, but the eventual FDA-approved product is subcutaneous and indicated in premenopausal women. The first-in-human evidence is Diamond et al. 2004, the Phase I dose-escalation study of intranasal PT-141 in healthy men and men with mild-to-moderate sildenafil-responsive erectile dysfunction. Diamond established the central-mechanism erectile response (statistically significant RigiScan-measured erectile activity at intranasal doses above 7 mg, including in the no-visual-stimulation healthy-male arm), the ~2-hour plasma half-life, and the dose-related flushing-and-nausea profile. The intranasal program was subsequently abandoned: at the doses required for reliable response in PDE5-non-responder populations, transient blood-pressure elevation became the gating safety concern, and Palatin migrated the program to a subcutaneous female-HSDD indication where the cardiovascular-comorbidity profile of the target population was more favorable.

The pivotal evidence that anchored the FDA approval is the paired RECONNECT trials, Kingsberg et al. 2019, which randomized 1,267 premenopausal women with acquired generalized hypoactive sexual desire disorder (HSDD) across two parallel Phase III studies of subcutaneous bremelanotide 1.75 mg on-demand versus placebo. Both trials met co-primary endpoints — statistically significant increases in sexual desire and reductions in associated distress as measured by validated patient-reported instruments. The FDA approved Vyleesi in June 2019. The labeled indication is narrow: premenopausal women with acquired generalized HSDD, on-demand dosing approximately 45 minutes before anticipated sexual activity, maximum of one dose per 24 hours and eight doses per month. The longitudinal-safety case rests on Simon et al. 2019, the 52-week open-label extension (n=684, up to 76 weeks of total exposure), which showed sustained efficacy and no new safety signals beyond the on-demand-use profile already characterized in the core trials. The same extension confirmed that nausea (40.4%), flushing (20.6%), and headache (12.0%) remain the dominant adverse events and do not attenuate with continued use — nausea, in particular, is the real-world adherence-limiting factor.

The mechanism story has been refined in the recent literature. Pfaus & Balon 2026, an editorial perspective in Journal of Clinical Psychopharmacology, revisits whether bremelanotide should be clinically considered for male sexual arousal and desire disorders despite the female-only label. The argument is mechanistic: central MC4R-mediated sexual-arousal pathways are not sex-specific, the preoptic-area dopamine-release substrate is conserved across sexes, and the absence of a pivotal male-HSDD trial reflects clinical-research-funding history rather than sex-specific biology. The authorship matters — Pfaus is the bench scientist whose 2004 female-rat solicitation work supplied the foundational mechanism for the female-population approval, so his explicit advocacy for considering male off-label use under specialist supervision is the strongest endorsement available in the peer-reviewed literature.

The honest framing has three parts. First, PT-141's approved indication is supported by more rigorous pivotal-trial evidence than most peptides on this site combined — the RECONNECT pair plus the Simon extension is regulatory-grade. Second, the dominant biohacker conversation is largely about off-label use (men, postmenopausal women, general sexual-function support) that sits on a thinner evidence base: the Diamond 2004 male Phase I, the Pfaus 2004 cross-species mechanism, and the Pfaus/Balon 2026 editorial argument together support clinical consideration, but there is no male-population RECONNECT analog. Third, the dose-limiting safety consideration is the transient blood-pressure elevation (up to ~6 mm Hg systolic, peaking within hours and returning toward baseline by ~6 hours), which is mechanism-derived and is the reason the intranasal male-ED program was abandoned. The sexual function decision guide walks the broader positioning versus PDE5 inhibitors and the trade-offs that drive practitioner choice.